Comparative analysis of Robotic-Assisted, Laparoscopic, and open radical nephrectomy: Utilization, Costs, and clinical outcomes

Minimally invasive approaches, including laparoscopic (LARN) and robotic-assisted radical nephrectomy (RARN), have gained adoption over open surgery (ORN) for renal cancer, despite RARN’s higher costs. This contemporary study evaluates trends in RARN, LARN, and ORN use and compares their hospital costs, clinical complications, and mortality rates. Patients undergoing radical nephrectomy (2016–2019) were identified from the National Inpatient Sample (NIS). Procedures were classified as RARN, LARN, or ORN using ICD-10 and Procedure Coding System codes. Patient demographics and comorbidities, hospital characteristics, length of stay (LOS), clinical complications, and hospital costs were analyzed. Trends in utilization were assessed, and regression models adjusted for patient and hospital factors examined associations between surgical approach and inpatient perioperative outcomes, including complications, mortality, LOS, and hospital costs. Among 154,115 patients, 39.5% underwent LARN, 25.7% RARN, and 34.8% ORN. Annual RARN utilization increased (21.8% to 29.6%), while LARN declined (44.8% to 35.2%). RARN was more common in older and comorbid patients. Median costs were lowest for LARN ($13,950) compared to RARN ($16,771) and ORN ($17,821). Both RARN and LARN had lower inpatient perioperative complications, blood transfusion rates, and mortality than ORN. RARN and LARN were associated with reduced LOS and costs relative to ORN. While RARN was 15% more expensive than LARN, it had 5% shorter LOS. A limitation was the absence of tumor characteristic data. RARN and LARN are increasingly used and both demonstrated better inpatient perioperative outcomes than ORN. However, RARN offers no clear clinical advantage over LARN and remains more costly than LARN.

Authors

Institutions

Publication Details

Journal
Journal of Robotic Surgery
Published
2025-11-24
DOI
https://doi.org/10.1007/s11701-025-02995-x
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative analysis of Robotic-Assisted, Laparoscopic, and open radical nephrectomy: Utilization, Costs, and clinical outcomes

Scott W. Keith, Patrick Moeller, Ruth J. Davis, Emmanuel F. Drabo et al.
Journal of Robotic Surgery
Renal cell carcinoma treatment
article

Comparative analysis of Robotic-Assisted, Laparoscopic, and open radical nephrectomy: Utilization, Costs, and clinical outcomes

Scott W. Keith, Patrick Moeller, Ruth J. Davis, Emmanuel F. Drabo, Costas D. Lallas, Vittorio Maio, Inkyu K Kim, Daniel Huang, Anushka Ghosh, R. Houston Thompson, Francisco Aguirre
article en

Abstract

Minimally invasive approaches, including laparoscopic (LARN) and robotic-assisted radical nephrectomy (RARN), have gained adoption over open surgery (ORN) for renal cancer, despite RARN’s higher costs. This contemporary study evaluates trends in RARN, LARN, and ORN use and compares their hospital costs, clinical complications, and mortality rates. Patients undergoing radical nephrectomy (2016–2019) were identified from the National Inpatient Sample (NIS). Procedures were classified as RARN, LARN, or ORN using ICD-10 and Procedure Coding System codes. Patient demographics and comorbidities, hospital characteristics, length of stay (LOS), clinical complications, and hospital costs were analyzed. Trends in utilization were assessed, and regression models adjusted for patient and hospital factors examined associations between surgical approach and inpatient perioperative outcomes, including complications, mortality, LOS, and hospital costs. Among 154,115 patients, 39.5% underwent LARN, 25.7% RARN, and 34.8% ORN. Annual RARN utilization increased (21.8% to 29.6%), while LARN declined (44.8% to 35.2%). RARN was more common in older and comorbid patients. Median costs were lowest for LARN ($13,950) compared to RARN ($16,771) and ORN ($17,821). Both RARN and LARN had lower inpatient perioperative complications, blood transfusion rates, and mortality than ORN. RARN and LARN were associated with reduced LOS and costs relative to ORN. While RARN was 15% more expensive than LARN, it had 5% shorter LOS. A limitation was the absence of tumor characteristic data. RARN and LARN are increasingly used and both demonstrated better inpatient perioperative outcomes than ORN. However, RARN offers no clear clinical advantage over LARN and remains more costly than LARN.

Journal of Robotic SurgeryVol. 20(1)
Johns Hopkins University (US), Thomas Jefferson University (US), Sidney Kimmel Cancer Center (US), Jefferson College (US)
Openalex Percentile: Top 45%
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.